MaxWell Biosciences

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Our novel drug class irreversibly inactivates humanity's top threat - highly infectious pandemic viruses. Maxwell's anti-infectives have been shown by multiple independent labs (including Stanford, NYU, Texas A&M, Baylor College of Medicine and others) to be rapid killers of the worst pathogens and appear safe in live animals and human cell cultures. In preclinical studies, many of Maxwell drug candidates are highly selective for pathogens over human cells, are biostable, effective at very low doses, and rapidly destroy currently untreatable pathogens. We are in preclinical stage now, preparing for human trials against the herpes virus.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Virucide
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Maxwell Biosciences